Published in Epigenetics on April 17, 2013
Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential. J Cell Mol Med (2014) 0.90
Bis-enoxacin blocks rat alveolar bone resorption from experimental periodontitis. PLoS One (2014) 0.84
Role of epithelial mesenchymal transition in prostate tumorigenesis. Curr Pharm Des (2015) 0.83
Bis-enoxacin inhibits bone resorption and orthodontic tooth movement. J Dent Res (2013) 0.83
Evidence for Critical Role of Lymphocyte Cytosolic Protein 1 in Oral Cancer. Sci Rep (2017) 0.75
A New Tool for in vivo Manipulation of Brain microRNA Levels: The Work of Smalheiser et al. (2014). Front Psychiatry (2015) 0.75
Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53. Vet Comp Oncol (2016) 0.75
A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein. PLoS One (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 37.83
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet (2010) 15.87
Non-coding RNAs in human disease. Nat Rev Genet (2011) 11.40
microRNAs as oncogenes and tumor suppressors. Dev Biol (2006) 10.68
MicroRNA expression profiling in prostate cancer. Cancer Res (2007) 8.04
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol (2009) 6.25
miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A (2008) 6.24
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Widespread deregulation of microRNA expression in human prostate cancer. Oncogene (2007) 5.70
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med (2012) 5.46
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol (2011) 4.01
Retracted A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet (2009) 3.88
Loss of mir-146a function in hormone-refractory prostate cancer. RNA (2008) 3.35
MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle (2005) 2.99
SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res (2007) 2.98
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer (2008) 2.67
miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene (2009) 2.61
Control of cell proliferation pathways by microRNAs. Cell Cycle (2008) 2.33
Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A (2011) 2.21
Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun (2008) 2.08
A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol (2008) 1.80
Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer (2002) 1.53
Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol (2011) 1.49
miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol Cancer Ther (2012) 1.45
Androgen regulation of micro-RNAs in prostate cancer. Prostate (2010) 1.30
The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Targets (2012) 1.29
MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells. Genes Cancer (2010) 1.28
Recent updates on the role of microRNAs in prostate cancer. J Hematol Oncol (2012) 1.15
The expanding role of fluoroquinolones. Am J Med (2002) 1.13
When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer (2008) 1.07
Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Ann Oncol (2008) 1.05
The therapeutic potential of microRNAs: disease modulators and drug targets. Pharm Res (2011) 1.01
miR-17* suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymes. PLoS One (2010) 0.98
The chemical and biological aspects of fluoroquinolones: reality and dreams. Curr Pharm Des (2001) 0.97
DNA extraction from tissue. Methods Mol Biol (2003) 0.93
The significance of strong histone deacetylase 1 expression in the progression of prostate cancer. Histopathology (2011) 0.90
A changing landscape in castration-resistant prostate cancer treatment. Front Endocrinol (Lausanne) (2012) 0.78
TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia (2006) 2.48
Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients. Eur Urol (2006) 2.19
A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res (2004) 2.06
Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res (2002) 1.88
Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol (2005) 1.80
Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res (2004) 1.76
Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl) (2006) 1.72
Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70
Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res (2010) 1.62
Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.62
Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol (2011) 1.49
P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res (2005) 1.36
High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res (2007) 1.30
BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol (2004) 1.27
Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res (2006) 1.22
TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics (2011) 1.20
MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.18
FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes Cancer (2011) 1.17
Human cancer cell antiproliferative and antioxidant activities of Juglans regia L. Food Chem Toxicol (2009) 1.14
Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology (2002) 1.11
8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res (2006) 1.11
Epigenetic biomarkers in urological tumors: A systematic review. Cancer Lett (2011) 1.09
Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol Cancer Res (2006) 1.09
Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer (2007) 1.06
Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes Cancer (2006) 1.04
Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance. Clin Cancer Res (2011) 1.04
Biallelic inactivation of the RIZ1 gene in human gastric cancer. Oncogene (2003) 1.04
Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia (2012) 1.03
Deregulated expression of selected histone methylases and demethylases in prostate carcinoma. Endocr Relat Cancer (2013) 1.03
Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin Cancer Res (2003) 1.03
Biological activities of Portuguese propolis: protection against free radical-induced erythrocyte damage and inhibition of human renal cancer cell growth in vitro. Food Chem Toxicol (2010) 1.01
Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol (2004) 1.01
I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2002) 1.00
Epigenetic regulation of Wnt signaling pathway in urological cancer. Epigenetics (2010) 0.99
Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Res Treat (2007) 0.99
Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer. Prostate (2008) 0.98
Epigenetic markers for molecular detection of prostate cancer. Dis Markers (2007) 0.96
Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol Oncol Res (2011) 0.96
Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol (2003) 0.96
Regulation of histone H2A.Z expression is mediated by sirtuin 1 in prostate cancer. Oncotarget (2013) 0.95
Expression and functionality of histone H2A variants in cancer. Oncotarget (2014) 0.95
Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. Cancer Genet (2011) 0.95
Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer. Genes Chromosomes Cancer (2011) 0.95
Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. BMC Cancer (2010) 0.94
Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. PLoS One (2011) 0.94
MSI phenotype and MMR alterations in familial and sporadic gastric cancer. Int J Cancer (2010) 0.94
A clinical case of Castleman's disease. J Thorac Oncol (2007) 0.94
Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer. BMC Genomics (2013) 0.93
High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. BMC Cancer (2013) 0.93
Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions. DNA Cell Biol (2005) 0.93
Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence. Innate Immun (2012) 0.92
A rapid and simple procedure for the establishment of human normal and cancer renal primary cell cultures from surgical specimens. PLoS One (2011) 0.92
Analysis of estrogen receptor polymorphism in codon 325 by PCR-SSCP in breast cancer: association with lymph node metastasis. Breast J (2002) 0.91
Helicobacter pylori induces increased expression of Toll-like receptors and decreased Toll-interacting protein in gastric mucosa that persists throughout gastric carcinogenesis. Helicobacter (2012) 0.91
High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. Breast Cancer Res Treat (2010) 0.91
ssDNA-binding protein 2 is frequently hypermethylated and suppresses cell growth in human prostate cancer. Clin Cancer Res (2008) 0.91
Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential. J Cell Mol Med (2014) 0.90
Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. Prostate (2012) 0.90
Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proc Natl Acad Sci U S A (2013) 0.89
Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer. Apoptosis (2010) 0.89
CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas. Mod Pathol (2009) 0.89
Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is associated with genomic complexity in clear cell kidney carcinomas. Cell Oncol (2008) 0.89
The epigenetics of renal cell tumors: from biology to biomarkers. Front Genet (2012) 0.89
Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies. Genes Chromosomes Cancer (2010) 0.88
Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas. Mol Cancer (2006) 0.88
Cocaine-induced kidney toxicity: an in vitro study using primary cultured human proximal tubular epithelial cells. Arch Toxicol (2011) 0.88
Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour. Eur J Endocrinol (2013) 0.88
Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes. Breast Cancer Res Treat (2013) 0.87
Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer. Biomed Pharmacother (2012) 0.87